Neos Therapeutics
Market Cap
US$38.3m
Last Updated
2021/03/07 00:45 UTC
Data Sources
Company Financials +
Executive Summary
Neos Therapeutics, Inc., a pharmaceutical company, develops, manufactures, and commercializes products for the treatment of attention deficit hyperactivity disorder (ADHD) using its drug delivery technology platform. More Details
Rewards
Risk Analysis
Snowflake Analysis
Reasonable growth potential with imperfect balance sheet.
Similar Companies
Share Price & News
How has Neos Therapeutics's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: NEOS is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 20% a week.
Volatility Over Time: NEOS's weekly volatility (20%) has been stable over the past year, but is still higher than 75% of US stocks.
Market Performance
7 Day Return
-9.6%
NEOS
-1.1%
US Pharmaceuticals
-0.4%
US Market
1 Year Return
-44.6%
NEOS
9.2%
US Pharmaceuticals
36.2%
US Market
Return vs Industry: NEOS underperformed the US Pharmaceuticals industry which returned 9.1% over the past year.
Return vs Market: NEOS underperformed the US Market which returned 36.3% over the past year.
Shareholder returns
| NEOS | Industry | Market | |
|---|---|---|---|
| 7 Day | -9.6% | -1.1% | -0.4% |
| 30 Day | -11.2% | -3.1% | -2.3% |
| 90 Day | 25.2% | 1.8% | 5.0% |
| 1 Year | -44.6%-44.6% | 12.9%9.2% | 39.1%36.2% |
| 3 Year | -91.4%-91.4% | 23.7%14.0% | 48.4%39.0% |
| 5 Year | -92.9%-92.9% | 43.8%26.8% | 116.6%92.4% |
Long-Term Price Volatility Vs. Market
How volatile is Neos Therapeutics's share price compared to the market and industry in the last 5 years?
Simply Wall St News
3 months ago | Simply Wall St
A Quick Analysis On Neos Therapeutics' (NASDAQ:NEOS) CEO Compensation5 months ago | Simply Wall St
When Will Neos Therapeutics, Inc. (NASDAQ:NEOS) Turn A Profit?9 months ago | Simply Wall St
What Kind Of Shareholders Own Neos Therapeutics, Inc. (NASDAQ:NEOS)?Valuation
Is Neos Therapeutics undervalued compared to its fair value and its price relative to the market?
In this section, we usually try to help investors determine whether Neos Therapeutics is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Neos Therapeutics has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.
This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.
Next Steps
- Take a look at Neos Therapeutics's forecasted future earnings and revenues from industry analysts to understand how the company is expected to perform in the future against its competitors and the wider market.
- Explore potentially undervalued companies in the Pharmaceuticals & Biotech industry.
Future Growth
How is Neos Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
60.2%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: NEOS is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2%).
Earnings vs Market: NEOS is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: NEOS's is expected to become profitable in the next 3 years.
Revenue vs Market: NEOS's revenue (17.3% per year) is forecast to grow faster than the US market (10% per year).
High Growth Revenue: NEOS's revenue (17.3% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if NEOS's Return on Equity is forecast to be high in 3 years time
Next Steps
Past Performance
How has Neos Therapeutics performed over the past 5 years?
16.0%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: NEOS is currently unprofitable.
Growing Profit Margin: NEOS is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: NEOS is unprofitable, but has reduced losses over the past 5 years at a rate of 16% per year.
Accelerating Growth: Unable to compare NEOS's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: NEOS is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-4.3%).
Return on Equity
High ROE: NEOS's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.
Next Steps
Financial Health
How is Neos Therapeutics's financial position?
Financial Position Analysis
Short Term Liabilities: NEOS has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Long Term Liabilities: NEOS has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Debt to Equity History and Analysis
Debt Level: NEOS has negative shareholder equity, which is a more serious situation than a high debt level.
Reducing Debt: NEOS's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: NEOS has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: NEOS has sufficient cash runway for 1.1 years if free cash flow continues to grow at historical rates of 9.5% each year.
Next Steps
Dividend
What is Neos Therapeutics's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate NEOS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate NEOS's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if NEOS's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if NEOS's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of NEOS's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
2.9yrs
Average management tenure
CEO
Jerry McLaughlin (52 yo)
2.75yrs
Tenure
US$1,374,155
Compensation
Mr. Gerald W. McLaughlin, also known as Jerry, MBA has been the Chief Executive Officer and President of Neos Therapeutics, Inc. since joined it on June 27, 2018 and its Director since June 2018. Mr. McLau...
CEO Compensation Analysis
Compensation vs Market: Jerry's total compensation ($USD1.37M) is above average for companies of similar size in the US market ($USD516.25K).
Compensation vs Earnings: Jerry's compensation has been consistent with company performance over the past year.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | 2.75yrs | US$1.37m | 0.049% $ 18.9k | |
| CFO, Treasurer & Corporate Secretary | 6.83yrs | US$647.25k | 0.059% $ 22.6k | |
| Vice President of Operations | no data | no data | no data | |
| Senior VP | 2yrs | US$678.95k | 0% $ 0 | |
| Chief Compliance Officer | 3.08yrs | no data | no data | |
| Vice President of Human Resources | 1.58yrs | no data | no data | |
| Senior Vice President of Research & Development | 3.17yrs | no data | no data |
2.9yrs
Average Tenure
52yo
Average Age
Experienced Management: NEOS's management team is considered experienced (2.9 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | 2.75yrs | US$1.37m | 0.049% $ 18.9k | |
| Independent Director | 11.75yrs | US$85.50k | 0.0030% $ 1.2k | |
| Independent Director | 5.5yrs | US$65.40k | 0% $ 0 | |
| Independent Director | 5.75yrs | US$91.75k | 0% $ 0 | |
| Independent Chairman | 11.75yrs | US$98.63k | 0.85% $ 326.0k | |
| Independent Director | 11.75yrs | US$90.50k | 0.11% $ 42.9k | |
| Independent Director | 2.92yrs | US$81.75k | 0% $ 0 | |
| Independent Director | 2.17yrs | US$91.86k | 0% $ 0 |
5.6yrs
Average Tenure
55yo
Average Age
Experienced Board: NEOS's board of directors are considered experienced (5.6 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
Neos Therapeutics, Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Neos Therapeutics, Inc.
- Ticker: NEOS
- Exchange: NasdaqGM
- Founded: 2009
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$38.313m
- Shares outstanding: 49.76m
- Website: https://www.neostx.com
Number of Employees
Location
- Neos Therapeutics, Inc.
- 2940 North Highway 360
- Suite 400
- Grand Prairie
- Texas
- 75050
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| NEOS | NasdaqGM (Nasdaq Global Market) | Yes | Common Stock | US | USD | Jul 2015 |
| NTE | DB (Deutsche Boerse AG) | Yes | Common Stock | DE | EUR | Jul 2015 |
Biography
Neos Therapeutics, Inc., a pharmaceutical company, develops, manufactures, and commercializes products for the treatment of attention deficit hyperactivity disorder (ADHD) using its drug delivery technolog...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2021/03/07 00:45 |
| End of Day Share Price | 2021/03/05 00:00 |
| Earnings | 2020/09/30 |
| Annual Earnings | 2019/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.